A Phase I Dose Escalation Study of MK0457 [VX 680, tozasertib] Evaluating the Safety Tolerability, Pharmacokinetics and Pharmacodynamics of a 24-Hour Continuous Infusion Given Every 21 Days in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2015
At a glance
- Drugs Tozasertib (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- 15 Jan 2008 The expected completion date for this trial is now 1 Nov 2007.
- 22 Dec 2007 Patient numbers, completion date and official title changed as per ClinicalTrials.gov.
- 19 Nov 2007 Status change from recruiting to terminated.